The Future of Health Care is Personalized Medicine | Diaceutics

The Future of Health Care is Personalized Medicine

July 10th, 2013

Peter Keeling

Peter Keeling comments on the Bill Frist article which discussed how personalized medicine will be the future of health care.

Bill Frist’s excellent article first published in the perhaps obscure G8 magazine and republished here (http://billfrist.com/future-of-healthcare-is-personalized-medicine/) has three personalized medicine messages we at Diaceutics promote:

  1. There is an unstoppable technological trajectory in genetics, molecular discovery and patient data which enables the personalizing of medicine. Bill’s focus is stem cells but this article could equally be about Minerva, Mount Sinai’s new super computer (http://blog.mountsinai.org/vision/2012/11/07/mount-sinais-supercomputer-ushers-in-a-new-era-2/) or the democratization of next generation sequencing as US oncology partners with Foundation Medicine to bring biological insight to the bedside of community oncologists (http://www.businesswire.com/news/home/20130530005411/en/Oncology-Network-Selects-med-fusion-Foundation-Medicine).
  2. Systems integration in health care, long recognized as a powerful key to unlock health care savings alongside profound clinical benefit, is itself enabled by personalized medicine. In particular, the integration of diagnostics, therapy and earlier biological insight to target disease higher up the treatment pathway will finally illustrate the power of personalized medicine. Our own research to illustrate how systems integration and PM2.0 are natural bedfellows continues (http://www.youtube.com/watch?v=78DfbmfuzTA).
  3. These changes herald transformative opportunities (rejuvenation as Bill calls it) for the pharmaceutical industry. We personally witness exciting fresh thinking every week now across those in our client base reorganizing around personalized medicine. The FDA, often accused of feet dragging, is disproportionately rewarding personalized medicine with faster approval times (http://www.forbes.com/sites/matthewherper/2013/06/23/the-fdas-cancer-czar-says-he-cant-approve-new-drugs-fast-enough/?commentId=comment_blogAndPostId/blog/comment/973-8540-8637).

But (there is always a but, right?) although Bill’s article covers the ‘why’ and ‘how’ he misses the ‘when’! Changes in personalized medicine appear to happen slowly and in a disconnected way, like mini tremors versus a major quake, in comparison perhaps to the popularization of consumer electronics and fast moving integrators like Google and Apple, whose product announcements can easily be connected with our understanding of a new ‘smart’ future. Consequently, it is hard to connect the ‘individual tremors’ in personalized medicine with the ‘future promise’. Many of our own friends in the industry believe personalized medicine will necessarily take a long time. However, to focus on the events rather than the underlying tectonic shifts ignores the fact that health care is being lined up for the big one. We will recognize this when it happens! Google buying AstraZeneca perhaps, because it provides (a very cost-effective) access to patients searching for better health care, or your eighteen year old daughter paying to have her genome mapped because she wants to control her own health care, or Lockheed Martin (masters of integration in defence technology) seeing the opportunity to sell PM2.0 to the US government. Like that other ‘big one’, we know it’s coming but we just don’t know when.

Blogs

View all blogs

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Case Studies

View all case studies

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications